Implementation of a care pathway for deep vein thrombosis: What's the benefit?
Jorn S. Heerink,
Nathalie Péquériaux,
Ruud Oudega,
Mathijn de Jong,
Hendrik Koffijberg,
Ron Kusters
Affiliations
Jorn S. Heerink
Department of Clinical Chemistry and Haematology, Jeroen Bosch Hospital, Henri Dunantstraat 1, 5223 GZ, ‘s-Hertogenbosch, the Netherlands.; Department of Clinical Chemistry and Haematology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands
Nathalie Péquériaux
Department of Clinical Chemistry and Haematology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands
Ruud Oudega
Department of Clinical Chemistry and Haematology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands
Mathijn de Jong
Department of Radiology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands
Hendrik Koffijberg
Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands
Ron Kusters
Department of Clinical Chemistry and Haematology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands
